NEW YORK — Pfizer and its German partner BioNTech will take its COVID-19 vaccine candidate with the fewest side effects into final-stage testing. In an online report Thursday, Pfizer researchers compared data from early-stage testing of two vaccine candidates. But one candidate caused considerably fewer injection reactions, particularly in older adults –symptoms such as fever, headache, chills, or muscle pain that are temporary but unpleasant, Pfizer reported. ADVERTISEMENTFinal testing of Pfizer’s lead candidate has begun as researchers recruit about 30,000 people in the U.S. and other countries. It generally takes years to develop a safe and effective vaccine for widespread use and distribution.

Source: Philippine Daily Inquirer August 20, 2020 18:45 UTC